For top Indian drug makers, the US market is the largest geography by sales, at 20-50 per cent of their consolidated revenues. Recently, Cadila Healthcare announced it was looking at doubling its sales over the next three years to reach the $1- billion mark in US sales from the current $553 million. Cadila has to grow this business at nearly 22 per cent annually to join the likes of Sun Pharmaceutical, Lupin, Dr Reddy’s and Aurobindo Pharma. From 24 per cent of overall sales in FY15, the US accounted for 40 per cent of Cadila’s sales in FY17. Kunal Randeria of Antique ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?